

Buccal epithelial cells display somatic, bone marrow–derived *CALR* mutation

Scott R. Gilles,^{1,*} Linda B. Baughn,^{1,2,*} Matthew L. Schomaker,¹ Elizabeth L. Courville,¹ Andrew C. Nelson,^{1,3,†} and Zohar Sachs^{3,4,†}

¹Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center Fairview, Minneapolis, MN; ²Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; ³Masonic Cancer Center and ⁴Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

Key Points

- Buccal epithelial cells harbor an MPN-associated *CALR* mutation in a patient with *CALR*-mutant essential thrombocytosis, Ph⁺ CML, and no germ line *CALR* mutation.

Introduction

CALR mutations are present in 70% to 84% of *JAK2* wild-type myeloproliferative neoplasms (MPNs).^{1,2} With rare exceptions, *CALR* mutations are mutually exclusive with *JAK2* or *MPL* mutations and have rarely been reported in conjunction with a *BCR-ABL1* translocation.³⁻⁶ Most cases of MPNs are sporadic, but 7% to 11% of cases have evidence of familial predisposition.⁷⁻⁹ Of these MPN families, approximately 60% have a single MPN phenotype in all affected kindreds, but the remaining 40% present with a variety of phenotypes. In such families, the propensity to develop MPNs, not the MPN-associated mutation, is hereditary. Accordingly, several MPN-predisposition alleles have been described.¹⁰⁻¹⁶ Different MPN-associated alterations can be found within the same family, including *BCR-ABL1* and mutations in *JAK2* and *CALR*.^{10,17} In familial MPNs, all *CALR* mutations identified have been somatic.¹⁸ Germ line mutations in *CALR* have not been described in MPNs but have been described in 0.6% of healthy patients without MPNs.¹⁹

The appropriate tissue to use for germ line studies in hematological malignancies is controversial because leukocytes infiltrate many tissues.^{20,21} Cultured fibroblasts, derived from skin biopsies, are the gold-standard germ line material^{10,20} but are costly and invasive to obtain. Hair follicles and nails clippings are readily available and generally free of leukocytes, but adequate DNA is difficult to obtain from these tissues. Many investigators use buccal swabs and washes for germ line tissue because these are easy to obtain and provide adequate DNA.^{19,22,23}

Case description

A 67-year-old woman with no significant medical history presented with abdominal pain. Peripheral blood (PB) revealed a marked leukocytosis, with a white blood cell (WBC) count of $160 \times 10^9/L$: 66% neutrophils, 16% myelocytes, 6.5% monocytes, 3.5% basophils, 2.5% promyelocytes, 2.5% metamyelocytes, 1.5% lymphocytes, and 1.5% blasts. She was nonanemic (hemoglobin [Hb], 12.7 g/dL) and had a normal platelet count ($340 \times 10^9/L$). Bone marrow (BM) biopsy revealed a hypercellular marrow (>90%) with myeloid-predominant trilineage hematopoiesis and 1% to 2% blasts. (Figure 1A-C). A subset of the megakaryocytes had increased nuclear-to-cytoplasmic ratios with hyperchromatic nuclei and irregularly shaped nuclear contours, which are not typically seen in CML but are common in essential thrombocythemia and primary myelofibrosis. Reticulin fibrosis was mildly increased (MF-1 of 3) by reticulin stain. Megakaryocytes appeared slightly increased in number, as can be seen in CML,²⁴ and were rarely clustered. Fluorescence in situ hybridization of PB identified a *BCR-ABL1* fusion in 98.5% of interphase cells, confirming a diagnosis of CML.

She started treatment with imatinib and achieved a hematological remission within 2.5 weeks. Ninety days later, polymerase chain reaction showed 6.56% *BCR-ABL1/ABL1* in the PB (a reduction




Figure 1. Chronic myeloid leukemia (CML) therapy unmarks effects of coexistent *CALR* mutation. (A-B) BM biopsy obtained at the time of CML diagnosis. Representative hematoxylin and eosin–stained sections from the core biopsy are shown at $\times 20$ (A) and $\times 40$ magnification (B). (A) Inset shows CD61 immunohistochemical stain highlighting megakaryocytes at $\times 20$ magnification. (C) Wright Giemsa–stained PB smear obtained at time of CML diagnosis. Original magnification $\times 50$. (D) *BCR-ABL1* fusion transcript and *CALR*-mutant allele frequency are quantitated in relationship to blood parameters as a function of time. Normal range of blood parameters is indicated by gray bars. (E-F) BM biopsy obtained at 6 months after initiation of imatinib therapy. Representative hematoxylin and eosin–stained sections from the core biopsy are shown at $\times 20$ (E) and $\times 40$ magnification (F). (F) Inset shows CD61 immunohistochemical stain highlighting megakaryocytes at $\times 20$ magnification.

from 69.7% at diagnosis; Figure 1D). However, at 90 days, her platelet count was elevated at $539 \times 10^9/L$, with normal WBC, Hb, and differential values. She had had a single complete blood count performed 9 years before CML presentation, with a platelet count of $600 \times 10^9/L$ and normal Hb, WBC, and differential values. No additional historic complete blood count was available. Thrombocytosis persisted for the subsequent follow-up period of >2 years, with a maximal platelet count of $584 \times 10^9/L$. A BM biopsy obtained 6 months after starting imatinib treatment showed resolution of the typical CML morphology in the myeloid lineage but persistent megakaryocytosis (Figure 1E-F). In addition, this biopsy showed more pronounced hyperchromatic and irregularly shaped megakaryocytes, as seen in non-CML MPNs.

Methods

Next-generation (NGS) and Sanger sequencing were performed. These studies were performed in accordance with the Declaration

of Helsinki and with approval of the University of Minnesota institutional review board.

Results and discussion

Given her thrombocytosis in the setting of appropriate molecular response to imatinib, a PB sample obtained after 90 days of imatinib underwent NGS of *JAK2*, *MPL*, and *CALR* genes. A 52-bp out-of-frame deletion in exon 9 of the *CALR* gene (NM_004343.3, p.Leu367fs*46) was detected, with a variant allele fraction (VAF) of 52% (Figures 1D and 2A). Material from her BM biopsy obtained at the time of CML diagnosis revealed the same 52-bp *CALR* deletion at a VAF of 63% (Figures 1D and 2A-B). A buccal specimen obtained 6 months after starting imatinib (day 174), when the *BCR-ABL1* transcript was 1% in the PB, harbored the *CALR* mutation at an allele frequency of 52% (Figures 1D and 2A,C). Cytospin and cell pellet preparations of her buccal material showed large cells with small, condensed nuclei and abundant cytoplasm,




Figure 2.

consistent with mature cells of epithelial origin (Figure 2D-G), without significant numbers of lymphocytes or macrophages. Accordingly, immunostaining was diffuse and strongly positive for cytokeratin AE1/AE3 and negative for CD45 (a panleukocyte marker) and OCT4 (an undifferentiated cell marker; Figure 2F-G; supplemental Figure 1A). SSE-A (CD15; found on multiple cell types including squamous epithelium and granulocytes) was weak to moderate in approximately half of the cells (supplemental Figure 1B). These findings indicate that the buccal cells were mature and epithelial without significant leukocyte contamination. A second buccal specimen, collected at day 194, showed the same *CALR* mutation at a VAF of 29%. NGS analysis of her day-194 BM specimen detected the *CALR* mutation at a VAF of 56%.

We analyzed buccal or blood samples from 2 daughters, a sister, and a brother of the case patient. None of these relatives harbored mutations in *JAK2*, *MPL*, or *CALR* via NGS. Next, we tested additional tissues from this patient to determine whether her *CALR* mutation was germ line or somatically acquired. The patient's PB was sorted based on CD3 and CD15 status and submitted for Sanger sequencing along with a hair follicle sample and banked DNA from prior samples (day-90 PB and day-194 BM and buccal specimen). Consistent with our NGS analyses, the *CALR* mutation was detected in her day-90 PB, day-194 BM, and day-194 buccal specimen by Sanger sequencing. Sanger sequencing also detected the *CALR* deletion in the CD15⁺ myeloid fraction, but this mutation was not detected in her CD3⁺ lymphocyte fraction or her hair follicle (Figure 2A,H-I). These findings confirm that her *CALR* deletion was somatically acquired and not germ line.

In this patient with *BCR-ABL*⁺ CML and preexisting *CALR*-mutant essential thrombocythemia, buccal mucosa epithelial cells harbored the *CALR* mutation, but PB-derived CD3⁺ lymphocytes and hair follicles did not harbor this mutation, consistent with a BM origin of her buccal epithelial cells. Two independent buccal samples displayed VAFs consistent with heterozygous status in a majority of tested cells.

These findings suggest that this patient's *CALR*-deleted progenitors may have engrafted her buccal mucosa and given rise to *CALR*-mutant buccal mucosa cells. Similarly, in a *JAK2*^{V617F}-mutant case where buccal testing showed a near 50% VAF, fingernail testing confirmed absence of a germ line mutation.²² These authors concluded that lymphocyte contamination was likely the cause of their erroneous results. In our case, we used cytokeratin AE1/AE3 staining and absence of CD45 to confirm that the buccal cells were epithelial and not lymphocytic. Our data suggest that BM-derived, *CALR*-mutant progenitor cells engrafted within our patient's buccal

mucosa, leading to a somatically acquired *CALR* mutation in her buccal epithelium. Although lymphocyte contamination of buccal material is well recognized,^{20,21} a BM origin for buccal epithelial cells is not well known. BM-derived cells have been shown to colonize cheek epithelium after allogeneic stem-cell transplantation,²⁵ but this has not been previously reported in a non-transplantation setting.

In some familial MPN studies, germ line status was demonstrated based on near 50% VAF in buccal tissue.^{19,22,23} Our case highlights the difficulty in selecting appropriate tissue for germ line testing and indicates that buccal epithelial tissue may not be a reliable source of germ line material.

Acknowledgments

Z.S. was supported by the American Cancer Society, Frederick A. DeLuca Foundation, and a Mentored Research Scholar Grant (MRSG-16-195-01-DDC); Clinical and Translational Science Institute, University of Minnesota, KL2 Career Development Awards ULI RR033183 and KL2 RR0333182 from the National Center for Advancing Translational Sciences, National Institutes of Health; the Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota; University of Minnesota Foundation donors; and a University of Minnesota Department of Medicine Women's Early Research Career Award.

Authorship

Contribution: S.R.G. obtained samples, analyzed data, performed pathological assessment of tissues, prepared figures, designed the study, and wrote the manuscript; L.B.B. analyzed data and designed the study; M.L.S. processed samples and performed experiments; E.L.C. performed pathological assessment of tissues and prepared figures; A.C.N. analyzed data, prepared figures, designed the study, and wrote the manuscript; and Z.S. obtained samples, designed the study, prepared figures, and wrote the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: Z.S., 0000-0001-9386-4163.

Correspondence: Zohar Sachs, Division of Hematology, Oncology, and Transplantation, Department Medicine, University of Minnesota, 420 Delaware St SE, MMC 480, Minneapolis, MN 55455; e-mail: sachs038@umn.edu; and Andrew C. Nelson, Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Fairview, 420 Delaware St SE, MMC 609, Minneapolis, MN 55455; e-mail: nels2055@umn.edu.

Figure 2. A somatic 52-bp deletion in the *CALR* gene is detected in buccal epithelial cells. (A) Table summarizing the detection of *CALR* mutation by NGS and Sanger sequencing in various tissues. (B-C) NGS of diagnostic BM (B) and buccal cells (C) visualized through Integrated Genome Viewer. Sequence reads are aligned to the *CALR* locus. Gray bars represent read alignments. White gaps in alignment represent areas of deletion. (D) Cytospin preparation of buccal cells stained with Diff-Quick (Romanowski) stain. (E-G) Paraffin-embedded buccal cell block stained with hematoxylin and eosin (E), cytokeratin AE1/AE3 (F), and CD45 (G). Original magnification $\times 40$ in panels D-G. (H) The *CALR* locus was amplified by polymerase chain reaction in PB, buccal mucosa, BM, CD3-selected PB lymphocytes, CD15-selected PB myeloid cells, and hair follicles from the patient and in a normal tissue control obtained from an unrelated donor. The amplified product was separated by electrophoresis on an agarose gel and stained with ethidium bromide. The wild-type and 52-bp-deleted *CALR* bands are indicated. (I) Sanger sequencing traces of the wild-type (upper panel) and mutant (lower panel) buccal sample, mapped to the reference *CALR* sequence. Bu, buccal mucosa; H, hair follicles; Ly, CD3-selected PB lymphocytes; My, CD15-selected PB myeloid cells; NC, normal tissue control.

References

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. *N Engl J Med*. 2013;369(25):2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. *N Engl J Med*. 2013;369(25):2391-2405.
3. Bonzheim I, Mankel B, Klapthor P, et al. CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation. *Blood*. 2015;125(14):2309-2311.
4. Cabagnols X, Cayuela JM, Vainchenker W. A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. *N Engl J Med*. 2015;372(7):688-690.
5. Seghatoleslami M, Ketabchi N, Ordo A, Asl JM, Golchin N, Saki N. Coexistence of p190 BCR/ABL transcript and CALR 52-bp deletion in chronic myeloid leukemia blast crisis: a case report. *Mediterr J Hematol Infect Dis*. 2016;8(1):e2016002.
6. Zamora L, Xicoy B, Cabezón M, et al. Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. *Leuk Lymphoma*. 2015;56(10):2973-2974.
7. Landgren O, Goldin LR, Kristinsson SY, Helgadóttir EA, Samuelsson J, Björkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. *Blood*. 2008;112(6):2199-2204.
8. Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. *Leukemia*. 2014;28(6):1357-1360.
9. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. *J Clin Oncol*. 2007;25(35):5630-5635.
10. Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. *Semin Oncol*. 2016;43(5):598-608.
11. Harutyunyan AS, Giambruno R, Krendl C, et al. Germline RBBP6 mutations in familial myeloproliferative neoplasms. *Blood*. 2016;127(3):362-365.
12. Hirvonen EAM, Pitkänen E, Hemminki K, Aaltonen LA, Kilpivaara O. Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera. *Hum Genomics*. 2017;11(1):6.
13. Rumi E, Cazzola M. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. *Br J Haematol*. 2017;178(5):689-698.
14. Rumi E, Harutyunyan AS, Pietra D, et al. LNK mutations in familial myeloproliferative neoplasms. *Blood*. 2016;128(1):144-145.
15. Saliba J, Saint-Martin C, Di Stefano A, et al. Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. *Nat Genet*. 2015;47(10):1131-1140.
16. Shen XH, Sun NN, Yin YF, et al. A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2 (V617F) and confers a proliferative potential on erythroid lineages. *Oncotarget*. 2016;7(8):9550-9560.
17. Jones AV, Cross NC. Inherited predisposition to myeloproliferative neoplasms. *Ther Adv Hematol*. 2013;4(4):237-253.
18. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. *Blood*. 2017;129(6):680-692.
19. Szuber N, Lamontagne B, Busque L. Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms [published online ahead of print 27 July 2016]. *J Clin Pathol*. doi:10.1136/jclinpath-2016-203940.
20. Churpek JE, Lorenz R, Nedumgottil S, et al. Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. *Leuk Lymphoma*. 2013;54(1):28-35.
21. Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. *J Clin Oncol*. 2017;35(9):1018-1028.
22. Lee J, Axilbund J, Dalton WB, et al. A polycythemia vera JAK2 mutation masquerading as a duodenal cancer mutation. *J Natl Compr Canc Netw*. 2016;14(12):1495-1498.
23. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. *PLoS Med*. 2006;3(7):e270.
24. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
25. Tran SD, Pillemer SR, Dutra A, et al. Differentiation of human bone marrow-derived cells into buccal epithelial cells in vivo: a molecular analytical study. *Lancet*. 2003;361(9363):1084-1088.